A promising new therapy that targets all of the Earlier talked about molecules may be the triple receptor agonist retatrutide.Early benefits recommend retatrutide could offer better still metabolic benefits that tirzepatide, although direct comparison trials are desired.When it continues to be unsure whether or not the kidney stone scenario was ins